Research Papers:

Tamoxifen improves cytopathic effect of oncolytic adenovirus in primary glioblastoma cells mediated through autophagy

Ilya V. Ulasov _, Nameeta Shah, Natalya V. Kaverina, Hwahyang Lee, Biaoyang Lin, Andre Lieber, Zaira G. Kadagidze, Jae-Guen Yoon, Brett Schroeder, Parvinder Hothi, Dhimankrishna Ghosh, Anatoly Y. Baryshnikov and Charles S. Cobbs

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:3977-3987. https://doi.org/10.18632/oncotarget.2897

Metrics: PDF 2129 views  |   HTML 2588 views  |   ?  


Ilya V. Ulasov1,4, Nameeta Shah1, Natalya V. Kaverina2,5, Hwahyang Lee1, Biaoyang Lin1, Andre Lieber3, Zaira G. Kadagidze2, Jae-Guen Yoon1, Brett Schroeder1, Parvinder Hothi1, Dhimankrishna Ghosh1, Anatoly Y. Baryshnikov2, Charles S. Cobbs1

1Swedish Neuroscience Institute, Seattle, WA, 98122, USA

2NN. Blokhin Cancer Research Center, RAMN, Moscow, Russia, 115478

3University of Washington, Seattle, WA, 98122, USA

4Institute of Experimental Diagnostic and Biotherapy, NN. Blokhin Cancer Research Center, RAMN, Moscow, Russia, 115478

5Current address: Division of Nephrology, University of Washington, Seattle, 98109, USA

Correspondence to:

Ilya V. Ulasov, e-mail: [email protected]

Charles S. Cobbs, e-mail: [email protected]

Keywords: brain tumor, adenovirus, survivin, CRAd, autophagy

Received: August 05, 2014     Accepted: December 11, 2014     Published: March 02, 2015


Oncolytic gene therapy using viral vectors may provide an attractive therapeutic option for malignant gliomas. These viral vectors are designed in a way to selectively target tumor cells and spare healthy cells. To determine the translational impact, it is imperative to assess the factors that interfere with the anti-glioma effects of the oncolytic adenoviral vectors. In the current study, we evaluated the efficacy of survivin-driven oncolytic adenoviruses pseudotyping with adenoviral fiber knob belonging to the adenoviral serotype 3, 11 and 35 in their ability to kill glioblastoma (GBM) cells selectively without affecting normal cells. Our results indicate that all recombinant vectors used in the study can effectively target GBM in vitro with high specificity, especially the 3 knob-modified vector. Using intracranial U87 and U251 GBM xenograft models we have also demonstrated that treatment with Conditionally Replicative Adenovirus (CRAd-S-5/3) vectors can effectively regress tumor. However, in several patient-derived GBM cell lines, cells exhibited resistance to the CRAd infection as evident from the diminishing effects of autophagy. To improve therapeutic response, tumor cells were pretreated with tamoxifen. Our preliminary data suggest that tamoxifen sensitizes glioblastoma cells towards oncolytic treatment with CRAd-S-5/3, which may prove useful for GBM in future experimental therapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2897